Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Sea Otter who wrote (706)	4/16/1999 12:56:00 PM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 2515

Sea Otter, Thanks for the news ort. I have expressed the same kind of wonder in many previous posts. All of the C225 results have been known for some time now (PII). Imagine my wonder when IMCL was trading at $8.00! I still can't understand it. Now we see from limited pancreatic results that there are some antiangiogenesis effects also. My only explanation is that skeptics abound. The skeptics are wrong. This stock is going through the roof when PIII results start coming in. Watch. Glad to see you aboard. [IMHO the skeptics are so numerous because IMCL chose a H&N cancer to begin trials with, a relatively easy cancer to treat with chemo, however, also characterized by high recurrence. I believe it's the recurrence part that investors are waiting to hear about.] Jackson